Cagrilintide vs Selank
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
CagrilintideCognitive Enhancement
Selank- Summary
- Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. Cagrilintide slows gastric emptying, suppresses glucagon, and reduces appetite via central amylin receptors. In combination with semaglutide (CagriSema), Phase 2 trials achieved approximately 15% body weight reduction. Phase 3 trials (REDEFINE program) are ongoing.
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- Half-Life
- ~7–10 days
- Minutes (but effects persist for hours)
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.16 mg → 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg
- 250–500 mcg
- Frequency
- Once weekly
- 1–3 times daily
- Key Benefits
- ~15% body weight reduction in combination with semaglutide (CagriSema Phase 2)
- Synergistic appetite suppression complementing GLP-1 receptor agonists
- Reduces post-meal glucagon excursions improving glycemic control
- Slows gastric emptying contributing to prolonged satiety
- Once-weekly dosing via subcutaneous injection
- Potential for greater weight loss than semaglutide monotherapy
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Decreased appetite
- Diarrhea
- +2 more
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Stacks With
- —
- —